Clinical trial
Efficacy of Low Dose Pegylated Interferon-α 2a Plus Ribavirin for the Treatment of Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients.
NCT00553930 is registered in ClinicalTrials.gov with Sociedad Andaluza de Enfermedades Infecciosas as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy of Low Dose Pegylated Interferon-α 2a Plus Ribavirin for the Treatment of Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients.
- Lead sponsor
- Sociedad Andaluza de Enfermedades Infecciosas
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- November 30, 2007
- Completion date
- May 31, 2010
- Enrollment
- 71 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.